Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Page 1
Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik M, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan E, Daly A, Dholaria B, Diaz Perez MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi PN, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Sohl M, Solomon SR, Ulrickson M, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wang T, Wirk B, Zeidan A, Litzow M, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Murthy HS, et al. Among authors: lazarus hm. Blood Adv. 2023 Nov 28;7(22):7007-7016. doi: 10.1182/bloodadvances.2023011308. Blood Adv. 2023. PMID: 37792849 Free PMC article.
Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for improved survival, whereas MAC-TBI predicted for less relapse and improved DFS. ...
Allo-HCT is effective in providing durable remissions and long-term survival in BPDCN. Younger age and allo-HCT in CR1 predicted for …
Racial and Socioeconomic Disparities in Long-Term Outcomes in 1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis.
Blue BJ, Brazauskas R, Chen K, Patel J, Zeidan AM, Steinberg A, Ballen K, Kwok J, Rotz SJ, Perez MAD, Kelkar AH, Ganguly S, Wingard JR, Lad D, Sharma A, Badawy SM, Lazarus HM, Hashem H, Szwajcer D, Knight JM, Bhatt NS, Page K, Beattie S, Arai Y, Liu H, Arnold SD, Freytes CO, Abid MB, Beitinjaneh A, Farhadfar N, Wirk B, Winestone LE, Agrawal V, Preussler JM, Seo S, Hashmi S, Lehmann L, Wood WA, Rangarajan HG, Saber W, Majhail NS. Blue BJ, et al. Among authors: lazarus hm. Transplant Cell Ther. 2023 Nov;29(11):709.e1-709.e11. doi: 10.1016/j.jtct.2023.07.013. Epub 2023 Jul 22. Transplant Cell Ther. 2023. PMID: 37482244
Whether the racial disparity in HCT outcomes persists in long-term survivors and possibly may be even exacerbated in this population, which frequently transitions back from the transplant center to their local healthcare providers, is unknown. In the current study, we comp …
Whether the racial disparity in HCT outcomes persists in long-term survivors and possibly may be even exacerbated in this population, …
Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia.
Wang J, Tomlinson B, Lazarus HM. Wang J, et al. Among authors: lazarus hm. Curr Treat Options Oncol. 2023 Jul;24(7):770-801. doi: 10.1007/s11864-023-01090-3. Epub 2023 May 17. Curr Treat Options Oncol. 2023. PMID: 37195589 Review.
While cytotoxic therapies can induce complete remission and even, at times, long-term survival, this approach is associated with significant toxic effects to visceral organs and worsening of immune dysfunction and marrow suppression leading to death. ...
While cytotoxic therapies can induce complete remission and even, at times, long-term survival, this approach is associated with sign …
Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.
Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Murthy HS, et al. Among authors: lazarus hm. Transplant Cell Ther. 2022 Apr;28(4):187.e1-187.e10. doi: 10.1016/j.jtct.2022.01.017. Epub 2022 Jan 23. Transplant Cell Ther. 2022. PMID: 35081472 Free PMC article.
T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. Previous studies of allogeneic hematopoietic cell transplantation (alloHCT) for T-PLL are limited by small numbers, and descriptions of patie …
T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. P …
Consolidation in AML: Abundant opinion and much unknown.
Weigert N, Rowe JM, Lazarus HM, Salman MY. Weigert N, et al. Among authors: lazarus hm. Blood Rev. 2022 Jan;51:100873. doi: 10.1016/j.blre.2021.100873. Epub 2021 Aug 5. Blood Rev. 2022. PMID: 34483002 Review.
Consolidation therapy forms the backbone of post-remission therapy for AML and is uniformly accepted as an integral part of therapy designed to achieve long-term survival. The need for post-remission therapy was initially described over four decades ago and has since under …
Consolidation therapy forms the backbone of post-remission therapy for AML and is uniformly accepted as an integral part of therapy designed …
Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation.
Mulroney CM, Abid MB, Bashey A, Chemaly RF, Ciurea SO, Chen M, Dandoy CE, Diaz Perez MA, Friend BD, Fuchs E, Ganguly S, Goldsmith SR, Kanakry CG, Kim S, Komanduri KV, Krem MM, Lazarus HM, Ljungman P, Maziarz R, Nishihori T, Patel SS, Perales MA, Romee R, Singh AK, Reid Wingard J, Yared J, Riches M, Taplitz R. Mulroney CM, et al. Among authors: lazarus hm. Br J Haematol. 2021 Jul;194(1):145-157. doi: 10.1111/bjh.17563. Epub 2021 Jun 14. Br J Haematol. 2021. PMID: 34124796 Free PMC article.
Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 214, 99% confidence interval (CI) 113-407; P = 0002] and inferior 2-year overall survival (HR 165, 99% CI 111-243; P = 0001) compared to SibCNI …
Patients in the HaploCy cohort who developed a CRVI by day +180 had both a higher risk of treatment-related mortality [hazard ratio (HR) 214 …
New cancer therapies. Are haematopoietic cell transplants a dead duck?
Gale RP, Phillips GL 2nd, Lazarus HM. Gale RP, et al. Among authors: lazarus hm. Bone Marrow Transplant. 2021 May;56(5):1086-1089. doi: 10.1038/s41409-020-01151-3. Bone Marrow Transplant. 2021. PMID: 33249425
The potential impact of current immune therapies on transplant activity is also limited because: (1) they predominately target B-cell rather than myeloid cancers; (2) many successful immune therapy recipients subsequently receive a transplant; (3) considerable data indicate much …
The potential impact of current immune therapies on transplant activity is also limited because: (1) they predominately target B-cell rather …
Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: A tale of misnomers, controversy and the unresolved.
Shallis RM, Gale RP, Lazarus HM, Roberts KB, Xu ML, Seropian SE, Gore SD, Podoltsev NA. Shallis RM, et al. Among authors: lazarus hm. Blood Rev. 2021 May;47:100773. doi: 10.1016/j.blre.2020.100773. Epub 2020 Oct 30. Blood Rev. 2021. PMID: 33213985 Review.
The World Health Organization classification and definition of "myeloid sarcoma" is imprecise and misleading. A more accurate term is "extramedullary acute myeloid leukemia tumor (eAML)." The pathogenesis of eAML has been associated with aberrancy of cellular adhesion mole …
The World Health Organization classification and definition of "myeloid sarcoma" is imprecise and misleading. A more accurate term is …
Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report.
Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Zhou Z, et al. Among authors: lazarus hm. Blood Adv. 2020 Jul 14;4(13):3180-3190. doi: 10.1182/bloodadvances.2019001266. Blood Adv. 2020. PMID: 32663298 Free PMC article.

NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P < .001). Long-term relapse was lower with FM (HR = 0.65, P < .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared wi

…

NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P < .001). Long-term relap

…
The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Hashmi S, Parsons S, Wood WA, Steinberg A, Freytes CO, Dandoy CE, Marks DI, Lazarus HM, Abdel-Azim H, Bitan M, Diaz MA, Olsson RF, Gergis U, Seber A, Wirk B, LeMaistre CF, Ustun C, Duncan C, Rizzieri D, Szwajcer D, Fagioli F, Frangoul H, Knight JM, Kamble RT, Mehta P, Schears R, Satwani P, Pulsipher MA, Aplenc R, Saber W. Arnold SD, et al. Among authors: lazarus hm. Biol Blood Marrow Transplant. 2020 Sep;26(9):1747-1756. doi: 10.1016/j.bbmt.2020.05.016. Epub 2020 May 25. Biol Blood Marrow Transplant. 2020. PMID: 32464284 Free PMC article.
In this retrospective cohort study, we examined the relationship between survival and HCU while investigating the hypothesis that matched sibling donor (MSD) alloHCT has significantly lower inpatient HCU with unrelated donor (URD) alloHCT, and that among URDs, umbilical cord bloo …
In this retrospective cohort study, we examined the relationship between survival and HCU while investigating the hypothesis that matched si …
90 results